Defining a Therapeutic Target for Ganciclovir Therapy in Immunocompromised Children With Cytomegalovirus Infection: A Brief Report

Maggie Gao; Heather Weerdenburg; Wenyu Yang; Xiao Zhu; Amanda Gwee

doi:10.1097/INF.0000000000004602

Defining a Therapeutic Target for Ganciclovir Therapy in Immunocompromised Children With Cytomegalovirus Infection: A Brief Report

Pediatr Infect Dis J. 2024 Oct 30. doi: 10.1097/INF.0000000000004602. Online ahead of print.

Authors

Maggie Gao¹, Heather Weerdenburg^{1

2}, Wenyu Yang^{3

4}, Xiao Zhu³, Amanda Gwee^{1

2

5}

Affiliations

¹ From the Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
² The Royal Children's Hospital, Melbourne, Victoria, Australia.
³ Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
⁴ Department of Pharmacy, Minhang Hospital, Fudan University, Shanghai, China.
⁵ Antimicrobial Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

PMID: 39486007
DOI: 10.1097/INF.0000000000004602

Abstract

Ganciclovir and valganciclovir are first-line treatments for cytomegalovirus in immunocompromised children; however, the optimal therapeutic target remains unclear. This review identified 6 studies that showed clearance of cytomegalovirus viremia occurs with a median area under the concentration-time curve (AUC24) between 23 and 70 μg·h/mL, with no clear correlation with efficacy or toxicity.